Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer

Next Previous
Search
Trial Profile

An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 1015 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man
  • Sponsors ArsenalBio

    • Most Recent Events

    • 06 May 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.
    • 06 May 2024 According to an ArsenalBio media release, data from this study will be highlighted at the American Society of Gene + Cell Therapy (ASGCT) annual meeting
    • 05 Jan 2023 According to an ArsenalBio media release, an update inclusive of information about the clinical trial will be provided during the company's upcoming presentation at the 41st Annual J.P. Morgan Healthcare Conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top